title: Oral albendazole for the treatment of cutaneous larva migrans.
abstract: Cutaneous larva migrans is becoming more common in the U.K. with the popularity of tropical countries as holiday destinations. We describe the increasing use of a new benzimidazole derivative, albendazole, which is very effective in the treatment of cutaneous larva migrans. In contrast to thiabendazole, it is virtually free from side-effects and should, we feel, become the treatment of choice for this condition.
authors.affiliation: Department of Dermatology, Bristol Royal Infirmary, Bristol, U.K.
authors.forename: S K
authors.initials: SK
authors.lastname: Jones
authors.forename: N J
authors.initials: NJ
authors.lastname: Reynolds
authors.forename: S
authors.initials: S
authors.lastname: Oliwiecki
authors.forename: R R
authors.initials: RR
authors.lastname: Harman
mesh_terms: D000284:Administration, Oral; D015766:Albendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D001940:Breast / Q000469:parasitology; D002081:Buttocks / Q000469:parasitology; D006801:Humans; D007815:Larva Migrans / Q000188:drug therapy* / Q000469:parasitology; D007868:Leg Dermatoses / Q000188:drug therapy / Q000469:parasitology
chemical_list: D015766:Albendazole